Structure Therapeutics Subsidiary Grants Genentech $100 Million License for GLP-1 Patents

Reuters01-06

Structure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Subsidiary Grants Genentech $100 Million License for GLP-1 Patents

Structure Therapeutics Inc. announced that its wholly-owned subsidiary, Gasherbrum Bio, Inc., has entered into a material agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. Under the agreement, Gasherbrum has granted Genentech and Roche a non-exclusive, sublicensable, royalty-bearing license to certain patents covering a class of oral GLP-1 receptor agonists distinct from aleniglipron. Genentech will make a one-time, non-refundable payment of $100 million to Gasherbrum and will pay royalties at a low single digit rate on net sales of products containing CT-996, a proprietary compound owned by Genentech. The agreement does not affect Structure Therapeutics’ ongoing programs or grant Genentech any patent prosecution or enforcement rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-000620), on January 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601683787?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601683787","market":"fut","top_or_hot":-1,"title":"Structure Therapeutics Subsidiary Grants Genentech $100 Million License for GLP-1 Patents","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Subsidiary Grants Genentech $100 Million License for GLP-1 Patents\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Structure Therapeutics Inc. announced that its wholly-owned subsidiary, Gasherbrum Bio, Inc., has entered into a material agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. Under the agreement, Gasherbrum has granted Genentech and Roche a non-exclusive, sublicensable, royalty-bearing license to certain patents covering a class of oral GLP-1 receptor agonists distinct from aleniglipron. Genentech will make a one-time, non-refundable payment of $100 million to Gasherbrum and will pay royalties at a low single digit rate on net sales of products containing CT-996, a proprietary compound owned by Genentech. The agreement does not affect Structure Therapeutics’ ongoing programs or grant Genentech any patent prosecution or enforcement rights.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-000620), on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Structure Therapeutics Subsidiary Grants Genentech $100 Million License for GLP-1 Patents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStructure Therapeutics Subsidiary Grants Genentech $100 Million License for GLP-1 Patents\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Subsidiary Grants Genentech $100 Million License for GLP-1 Patents\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Structure Therapeutics Inc. announced that its wholly-owned subsidiary, Gasherbrum Bio, Inc., has entered into a material agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. Under the agreement, Gasherbrum has granted Genentech and Roche a non-exclusive, sublicensable, royalty-bearing license to certain patents covering a class of oral GLP-1 receptor agonists distinct from aleniglipron. Genentech will make a one-time, non-refundable payment of $100 million to Gasherbrum and will pay royalties at a low single digit rate on net sales of products containing CT-996, a proprietary compound owned by Genentech. The agreement does not affect Structure Therapeutics’ ongoing programs or grant Genentech any patent prosecution or enforcement rights.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-000620), on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GPCR","symbol_name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL4Rz0qt:1","article_id":"2601683787","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601683787","pubTimestamp":1767647295,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Structure Therapeutics Inc. announced that its wholly-owned subsidiary, Gasherbrum Bio, Inc., has entered into a material agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. Under the agreement, Gasherbrum has granted Genentech and Roche a non-exclusive, sublicensable, royalty-bearing license to certain patents covering a class of oral GLP-1 receptor agonists distinct from aleniglipron. Genentech will make a one-time, non-refundable payment of $100 million to Gasherbrum and will pay royalties at a low single digit rate on net sales of products containing CT-996, a proprietary compound owned by Genentech. The agreement does not affect Structure Therapeutics’ ongoing programs or grant Genentech any patent prosecution or enforcement rights.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4599":"减肥药","BK4007":"制药"},"translate_title":"Structure Therapeutics子公司授予基因泰克1亿美元的GLP-1专利许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPCR":0.9},"content_text":"Structure Therapeutics Subsidiary Grants Genentech $100 Million License for GLP-1 Patents\n    \n\n        Structure Therapeutics Inc. announced that its wholly-owned subsidiary, Gasherbrum Bio, Inc., has entered into a material agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. Under the agreement, Gasherbrum has granted Genentech and Roche a non-exclusive, sublicensable, royalty-bearing license to certain patents covering a class of oral GLP-1 receptor agonists distinct from aleniglipron. Genentech will make a one-time, non-refundable payment of $100 million to Gasherbrum and will pay royalties at a low single digit rate on net sales of products containing CT-996, a proprietary compound owned by Genentech. The agreement does not affect Structure Therapeutics’ ongoing programs or grant Genentech any patent prosecution or enforcement rights.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-000620), on January 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601683787","isCrawlerRequest":true}